On October 20, 2025 Archivel Farma reported the outcome of RUTIVAC study in Bladder Cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The RUTI vaccine, developed and produced in-house by Archivel Farma, was tested in a phase I trial involving 40 patients with high-risk non-muscle-invasive bladder cancer at Hospital Universitari Germans Trias i Pujol. Administered prior to standard BCG therapy, RUTI enhanced the immune response, reducing tumor recurrence and progression, and improving patient survival over five years.

The vaccine generated stronger CD4⁺ and CD8⁺ T-cell responses and increased cytokine production, without promoting immunosuppressive T-regulatory cells. Importantly, RUTI was well tolerated with only mild injection-site reactions.
These promising results, published in European Urology, suggest that RUTI could enhance the current standard of care for bladder cancer, paving the way for larger trials to confirm its clinical benefits. Read in View Source

Archivel Farma has been both, sponsor and RUTI supplier for this study. We extend our sincere thanks and congratulations to our partners, IrsiCaixa and the Germans Trias i Pujol Research Institute (IGTP), for their dedication and excellent work.

(Press release, Archivel Farma, OCT 20, 2025, View Source [SID1234656810])